FDA Alert on the Anti-Diabetes Drug Avandia:
Risk of Heart Attack
The U.S. Food and Drug Administration (FDA) has issued a warning regarding Avandia (rosiglitazone), a drug approved to treat type 2 diabetes. Data from clinical trials have shown that there is a potentially significant increase in the risk of heart attack and heart-related deaths in patients taking Avandia.
The FDA recommends that people who are prescribed Avandia, especially those who are known to have underlying heart disease or who are at high risk of heart attack, should discuss with a medical profession this new warning as they weigh the treatment options for their type 2 diabetes.
The FDA also stresses that there is an inherent risk to switching patients with diabetes from one treatment to another even in the absence of specific risks associated with particular treatments.
Avandia is manufactured by GlaxoSmithKline, which is based in Research Triangle Park, N.C.
If you or a loved one has suffered cardiac complications after ingesting Avandia, you deserve the guidance of a knowledgeable drug attorney. Get a free case review by filling out the form below.
see also:
Experts Cite Risks
Federal Scientist: Pull Avandia From the Market Because of Heart RisksPanel Convenes, Scientist Recommends Taking Avandia off the Market
Veterans Affairs: Avandia
Veterans Affairs Severely Limits Use of GlaxoSmithKline's Avandia DrugVeterans Affairs Limits Use of Glaxo's Avandia Due to Safety Concerns
News & Warnings
Avandia Breaking News: Glaxo Warned in 2001 about Misleading MarketingBloomberg News: FDA Warned Glaxo about Avandia Marketing in 2001
